Dr. Farago on Combination of Olaparib and Temozolomide in Small Cell Lung Cancer
In Partnership With:
Anna Farago, MD, PhD, assistant, Medicine, Massachusetts General Hospital Cancer Center, and instructor, Medicine, at Harvard Medical School, discusses the combination of olarparib (Lynparza) and temozolomide (Temodar) for patients with small cell lung cancer (SCLC).
Anna Farago, MD, PhD, assistant, Medicine, Massachusetts General Hospital Cancer Center, and instructor, Medicine, at Harvard Medical School, discusses the combination of olaparib (Lynparza) and temozolomide (Temodar) for patients with small cell lung cancer (SCLC).
There is a phase I study investigating the combination of olaparib and temozolomide in patients with SCLC who have had progression after 1 prior line of platinum-based chemotherapy, explains Farago. This was designed as a 3 + 3 dose-escalation study, which escalated patients through 4 doses of the combination therapy.
The doses were found to be relatively tolerable, states Farago. The progression-free survival was 5.6 months with the median duration of treatment for patients being 5 months with some treated up to 1 year.
